Discovery and saturation analysis of cancer genes across 21 tumour types
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Although a few cancer genes are mutated in a high proportion of tumours of a given type (>20%), most are mutated at intermediate frequencies (2-20%). To explore the feasibility of creating a comprehensive catalogue of cancer genes, we analysed somatic point mutations in exome sequences from 4,742 human cancers and their matched normal-tissue samples across 21 cancer types. We found that large-scale genomic analysis can identify nearly all known cancer genes in these tumour types. Our analysis also identified 33 genes that were not previously known to be significantly mutated in cancer, including genes related to proliferation, apoptosis, genome stability, chromatin regulation, immune evasion, RNA processing and protein homeostasis. Down-sampling analysis indicates that larger sample sizes will reveal many more genes mutated at clinically important frequencies. We estimate that near-saturation may be achieved with 600-5,000 samples per tumour type, depending on background mutation frequency. The results may help to guide the next stage of cancer genomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, the dysregulation of chromatin looping may be causally related to carcinogenesis (Extended Data Fig. 7a) 31,32.”
From The structural basis for cohesin–CTCF-anchored loops (2020) · cites this paper as [31]
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“The process of tumor development is strongly related to the dysfunctions caused by TP53 mutations.3,4”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
In the citing paper
“Most TP53 mutations are missense mutations located in the DBD.3,4,203,205,380”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“(5) Chromatin regulation—Five genes are associated with chromatin regulation.”
Self-citationMutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053 · cited 1×
“(4) Genome stability—Six genes encode proteins related to genome stability.”
BackgroundSelf-citationPan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C.-Z., Wala, J., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,870 · cited 1×
“(7) RNA processing—Three genes are associated with RNA processing and metabolism.”
BackgroundSelf-citationMapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · cited 4×
“We ask: (1) Can large-scale genomic analysis across tumor types reliably identify all known cancer genes? (2) Will it reveal many new candidate cancer genes? (3) How far do we stand from having a complete catalog of cancer genes – at least those of intermediate frequency? We used rigorous statistical methods to enumer…”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 701–800 of 1,017
COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
Synnott, N. C., O’Connell, D., Crown, J., & Duffy, M. J. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05435-1 · Cited by 77
Revisiting determinants of prognosis in cutaneous melanoma
Weiss, S. A., Hanniford, D., Hernando, E., & Osman, I. (2015) · Cancer · doi:10.1002/cncr.29634 · Cited by 87
Human adaptive immune receptor repertoire analysis—Past, present, and future
Nielsen, S. C. A., & Boyd, S. D. (2018) · Immunological Reviews · doi:10.1111/imr.12667 · Cited by 89
Detailed modeling of positive selection improves detection of cancer driver genes
Zhao, S., Liu, J., Nanga, P., Liu, Y., Çiçek, A. E., Knoblauch, N., He, C., Stephens, M., & He, X. (2019) · Nature Communications · doi:10.1038/s41467-019-11284-9 · Cited by 79
“Nonetheless, many important driver genes likely remain undiscovered 3 , especially in cancers with low-sample sizes.”
BackgroundDiscovery and Features of an Alkylating Signature in Colorectal Cancer
Gurjao, C., Zhong, R., Haruki, K., Li, Y. Y., Spurr, L. F., Lee-Six, H., Reardon, B. M., Ugai, T., Zhang, X., Cherniack, A. D., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1656 · Cited by 90
“The pipeline employs the following tools: MuTect (29), ContEst (30), Strelka (31), DeTiN (32), AllelicCapSeg (33), MAFPoNFilter (34), RealignmentFilter, GATK (35), and PicardTools.”
Role of Akt Activation in PARP Inhibitor Resistance in Cancer
Gallyas, F., Sümegi, B., & Szabó, C. (2020) · Cancers · doi:10.3390/cancers12030532 · Cited by 81
Jian, M., Ren, L., He, G., Lin, Q., Tang, W., Chen, Y., Chen, J., Liu, T., Ji, M., Wei, Y., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02407-8 · Cited by 78
Koninck, M. D., & Losada, A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026476 · Cited by 88
“Recent pan-cancer studies have placed cohesin and its regulators among the networks most frequently mutated in cancer (Kandoth et al. 2013; Lawrence et al. 2014; Leiserson et al. 2015).”
BackgroundWang, L., Fan, J., Francis, J. M., Georghiou, G. P., Hergert, S., Li, S., Gambe, R. G., Zhou, C. W., Yang, C., Xiao, S., et al. (2017) · Genome Research · doi:10.1101/gr.217331.116 · Cited by 83
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma
Ghosh, A. P., Marshall, C. B., Coric, T., Shim, E.-H., Kirkman, R., Ballestas, M. E., Ikura, M., Bjornsti, M.-A., & Sudarshan, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4963 · Cited by 77
Yamamoto, H., Watanabe, Y., Maehata, T., Morita, R., Yoshida, Y., Oikawa, R., Ishigooka, S., Ozawa, S.-I., Matsuo, Y., Hosoya, K., et al. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3927 · Cited by 86
Evaluating somatic tumor mutation detection without matched normal samples
Teer, J. K., Zhang, Y., Chen, L., Welsh, E. A., Cress, W. D., Eschrich, S. A., & Berglund, A. (2017) · Human Genomics · doi:10.1186/s40246-017-0118-2 · Cited by 75
Zhang, Y., Chen, F., Fonseca, N. A., He, Y., Fujita, M., Nakagawa, H., Zhang, Z., Brāzma, A., PCAWG Transcriptome Working Group, Amin, S. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13885-w · Cited by 81
Self-citationA fork in the road: Where homologous recombination and stalled replication fork protection part ways
Tye, S., Ronson, G. E., & Morris, J. R. (2021) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.07.004 · Cited by 77
Tumor suppressor p53: from engaging DNA to target gene regulation
Sammons, M. A., Nguyen, T.-A. T., McDade, S. S., & Fischer, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa666 · Cited by 77
Tracking and interpreting long-range chromatin interactions with super-resolution live-cell imaging
Brandão, H. B., Gabriele, M., & Hansen, A. S. (2021) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2020.11.002 · Cited by 77
Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma
Fan, C., Chen, L., Huang, Q., Shen, T., Welsh, E. A., Teer, J. K., Cai, J., Cress, W. D., & Wu, J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.378 · Cited by 78
“Also, no CDKN3 mutation in lung cancer is found in the Broad Institute’s tumorportal database (www.tumorportal.org) (Lawrence et al, 2014).”
BackgroundBennett, J. A., Weigelt, B., Chiang, S., Selenica, P., Chen, Y., Bialik, A., Bi, R., Schultheis, A. M., Lim, R. S., Ng, C. K. Y., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.56 · Cited by 81
“29 In addition, we assessed whether the variants affected cancer genes as defined by Kandoth et al. 30 , the Cancer Gene Census 31 or Lawrence et al. 32 , as previously described.”
MethodMeasuring Clonal Evolution in Cancer with Genomics
Williams, M. J., Sottoriva, A., & Graham, T. A. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021712 · Cited by 103
Composition and Function of Mutant Swi/Snf Complexes
Dutta, A., Sardiu, M. E., Gogol, M., Gilmore, J. M., Zhang, D., Florens, L. A., Abmayr, S. M., Washburn, M. P., & Workman, J. L. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.058 · Cited by 78
Comparison of algorithms for the detection of cancer drivers at subgene resolution
Porta-Pardo, E., Kamburov, A., Tamborero, D., Pons, T., Grases, D., Valencia, A., Lopez-Bigas, N., Getz, G., & Godzik, A. (2017) · Nature Methods · doi:10.1038/nmeth.4364 · Cited by 76
“Type III algorithms compare the number of mutations in the selected region with that of the rest of the protein to determine whether there is enrichment in somatic mutations in specific domains or regions.”
BackgroundSelf-citationLu, J., Qian, J., Xu, Z., Yin, S., Zhou, L., Zheng, S., & Zhang, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.631486 · Cited by 85
Obesity: a perfect storm for carcinogenesis
Harris, B. H. L., Macaulay, V. M., Harris, D. A., Klenerman, P., Karpe, F., Lord, S., Harris, A. L., & Buffa, F. M. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10046-2 · Cited by 88
African-specific molecular taxonomy of prostate cancer
Jaratlerdsiri, W., Jiang, J., Gong, T., Patrick, S. M., Willet, C. E., Chew, T., Lyons, R. J., Haynes, A., Pasqualim, G., Louw, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05154-6 · Cited by 78
Aberrant RSPO3-LGR4 signaling in Keap1-deficient lung adenocarcinomas promotes tumor aggressiveness
Gong, X., Yi, J., Carmon, K. S., Crumbley, C., Xiong, W., Thomas, A., Fan, X., Guo, S., An, Z., Chang, J. T., et al. (2014) · Oncogene · doi:10.1038/onc.2014.417 · Cited by 93
The butterfly effect in cancer: A single base mutation can remodel the cell
Hart, J. R., Zhang, Y., Liao, L., Ueno, L. A., Du, L., Jonkers, M., Yates, J. R., & Vogt, P. K. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424012112 · Cited by 89
The genetic landscape of breast carcinomas with neuroendocrine differentiation
Marchiò, C., Geyer, F. C., Ng, C. K. Y., Piscuoglio, S., Filippo, M. R. D., Cupo, M., Schultheis, A. M., Lim, R. S., Burke, K. A., Guerini‐Rocco, E., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4837 · Cited by 78
p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes
Pappas, K., Xu, J., Zairis, S., Resnick-Silverman, L., Abate, F., Steinbach, N., Ozturk, S., Saal, L. H., Su, T., Cheung, P., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0089 · Cited by 75
Pareja, F. G., Geyer, F. C., Kumar, R., Selenica, P., Piscuoglio, S., Ng, C. K. Y., Burke, K. A., Edelweiss, M., Murray, M. P., Brogi, E., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0042-6 · Cited by 80
Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling
Oldrini, B., Curiel-García, Á., Marques, C., Matia, V., Uluçkan, Ö., Graña-Castro, O., Torres-Ruiz, R., Rodriguez-Perales, S., Huse, J. T., & Squatrito, M. (2018) · Nature Communications · doi:10.1038/s41467-018-03731-w · Cited by 76
Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas
Wang, X., Waschke, B. C., Woolaver, R. A., Chen, Z., Zhang, G., Piscopio, A. D., Liu, X., & Wang, J. H. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0875 · Cited by 83
Peng, Q., Wang, C., Chen, H., Zhang, R., Pan, Z., Lu, Z., Wang, G., Yue, X., Huang, W., & Liu, R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001638 · Cited by 79
Zhao, Q., Wang, F., Chen, Y., Chen, S., Yao, Y.-C., Zeng, Z.-L., Jiang, T., Wang, Y., Wu, C., Jing, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30062-8 · Cited by 90
Suzuki, M., Shiraishi, K., Yoshida, A., Shimada, Y., Suzuki, K., Asamura, H., Furuta, K., Kohno, T., & Tsuta, K. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.10.014 · Cited by 79
Keap1/Nrf2 pathway in the frontiers of cancer and non-cancer cell metabolism
Chartoumpekis, D. V., Wakabayashi, N., & Kensler, T. W. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150049 · Cited by 75
An ecosystem of cancer cell line factories to support a cancer dependency map
Boehm, J. S., & Golub, T. R. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3967 · Cited by 72
Self-citationHuang, A. Y., Zhang, Z., Ye, A. Y., Dou, Y., Yan, L., Yang, X., Zhang, Y., & Wei, L. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx024 · Cited by 75
Recent progress in the study of the Rheb family GTPases
Heard, J. J., Fong, V., Bathaie, S. Z., & Tamanoi, F. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.05.011 · Cited by 84
Hung, R. J., Ulrich, C. M., Goode, E. L., Brhane, Y., Muir, K. R., Chan, A. T., Marchand, L. L., Schildkraut, J. M., Witte, J. S., Eeles, R. A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv246 · Cited by 82
The ubiquitin ligase adaptor SPOP in cancer
Cuneo, M. J., & Mittag, T. (2019) · FEBS Journal · doi:10.1111/febs.15056 · Cited by 78
MLL3 loss drives metastasis by promoting a hybrid epithelial–mesenchymal transition state
Cui, J., Zhang, C., Lee, J., Bartholdy, B., Yang, D., Liu, Y., Erler, P., Galbo, P. M., Hodge, D. Q., Huangfu, D., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01045-0 · Cited by 78
Kunze, K., Spieker, T., Gamerdinger, U., Nau, K., Berger, J., Dreyer, T., Sindermann, J. R., Hoffmeier, A., Gattenlöhner, S., & Bräuninger, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1162 · Cited by 75
Wijdeven, R. H. M., Pang, B., van der Zanden, S. Y., Qiao, X., Blomen, V. A., Hoogstraat, M., Lips, E. H., Janssen, L., Wessels, L. F. A., Brummelkamp, T. R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0380 · Cited by 80
Xiao, D., Pan, H., Li, F., Wu, K., Zhang, X., & He, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8213 · Cited by 86
Geyer, F. C., Berman, S., Marchiò, C., Burke, K. A., Guerini‐Rocco, E., Piscuoglio, S., Ng, C. K. Y., Pareja, F. G., Wen, H. Y., Hódi, Z., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.161 · Cited by 80
Lazzari, L., Corti, G., Picco, G., Isella, C., Montone, M., Arcella, P., Durinikova, E., Zanella, E. R., Novara, L., Barbosa, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3440 · Cited by 74
“The putative biological significance in cancer of these private mutations identified only in XLs (n=4174) or PDXs (n=1997) was assessed on Cancer Gene Census and data reported from CRC analysis (35,36).”
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
Tamborero, D., Rubio-Perez, C., Deu-Pons, J., Schroeder, M. P., Vivancos, A., Rovira, A., Tusquets, I., Albanell, J., Rodon, J., Tabernero, J., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/140475 · Cited by 74
Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
Wang, J., Khiabanian, H., Rossi, D., Fabbri, G., Gattei, V., Forconi, F., Laurenti, L., Marasca, R., Poeta, G. D., Foà, R., et al. (2014) · eLife · doi:10.7554/elife.02869 · Cited by 76
“unknown (Futreal et al., 2004; Greenman et al., 2007; Santarius et al., 2010; Lawrence et al., 2014).”
InfluentialTan, S., Petrovics, G., & Srivastava, S. K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041255 · Cited by 83
“Thus, large sample sizes are required to establish the power to detect mutations confidently above the background rate [215].”
BackgroundSystematic discovery of mutation-directed neo-protein-protein interactions in cancer
Mo, X., Niu, Q., Ivanov, A. A., Tsang, Y. H., Tang, C., Shu, C., Li, Q., Qian, K., Wahafu, A., Doyle, S. P., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.014 · Cited by 77
Sahafnejad, Z., Ramazi, S., & Allahverdi, A. (2023) · Genes · doi:10.3390/genes14040873 · Cited by 80
Cheng, F., Liu, C., Lin, C.-C., Zhao, J., Jia, P., Li, W., & Zhao, Z. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004497 · Cited by 77
Tumor protein D52 (TPD52) and cancer—oncogene understudy or understudied oncogene?
Byrne, J. A., Frost, S., Chen, Y., & Bright, R. K. (2014) · Tumor Biology · doi:10.1007/s13277-014-2006-x · Cited by 76
Pediatric low-grade gliomas: How modern biology reshapes the clinical field
Bergthold, G., Bandopadhayay, P., Bi, W. L., Ramkissoon, L. A., Stiles, C. D., Segal, R. A., Beroukhim, R., Ligon, K. L., Grill, J., & Kieran, M. W. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.02.004 · Cited by 83
Mennonna, D., Maccalli, C., Romano, M. C., Garavaglia, C., Capocefalo, F., Bordoni, R., Severgnini, M., Bellis, G. D., Sidney, J., Sette, A., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-309453 · Cited by 76
Jain, P., Fierst, T. M., Han, H. J., Smith, T. L., Vakil, A., Storm, P. B., Resnick, A. C., & Waanders, A. J. (2017) · Oncogene · doi:10.1038/onc.2017.276 · Cited by 77
“We previously identified QKI’s contribution as a fusion partner in MYB-QKI fusion in angiocentric gliomas 18 , corroborating previous findings that QKI deletions are oncogenic in cancers such as glioblastomas 19, 20 , prostate cancer 21 , lung cancer 22 and gastric cancer 23 .”
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 84
Nucleosome and ubiquitin position Set2 to methylate H3K36
Bilokapić, S., & Halić, M. (2019) · Nature Communications · doi:10.1038/s41467-019-11726-4 · Cited by 69
A comprehensive characterization of cis -acting splicing-associated variants in human cancerPreprint
Shiraishi, Y., Kataoka, K., Chiba, K., Okada, A., Kogure, Y., Tanaka, H., Ogawa, S., & Miyano, S. (2018) · Genome Research · doi:10.1101/gr.231951.117 · Cited by 73
Rapid Generation of Somatic Mouse Mosaics with Locus-Specific, Stably Integrated Transgenic Elements
Kim, G. B., Pacheco, D. R. F., Saxon, D. S., Yang, A., Sabet, S., Dutra‐Clarke, M., Levy, R., Watkins, A., Park, H., Akhtar, A. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.013 · Cited by 79
“With the identification of hundreds of recurrent putative cancer-driver mutations, many of which are gain-of-function (GOF) oncogenes, it is imperative to create a tractable in vivo platform that canmodel these potential oncogenes, especially in conjunction with loss-of-function (LOF) tumor suppressor mutations (Lawre…”
The Role of the Microbiome in the Etiopathogenesis of Colon Cancer
Tekle, G. E., Andreeva, N., & Garrett, W. S. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-025619 · Cited by 88
Focal chromosomal copy number aberrations in cancer—Needles in a genome haystack
Krijgsman, O., Carvalho, B. G., Meijer, G. A., Steenbergen, R. D. M., & Ylstra, B. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.08.001 · Cited by 82
A versatile modular vector system for rapid combinatorial mammalian genetics
Albers, J., Danzer, C., Rechsteiner, M., Lehmann, H., Brandt, L. P., Hejhal, T., Catalano, A., Busenhart, P., Gonçalves, A. F., Brandt, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79743 · Cited by 71
“The application of genomic technologies to the study of cancers has revolutionized our understanding of the genetic landscapes of tumors (1, 2); however, functional studies are required to make sense of these cataloguing efforts to determine how different combinations of the many candidate genetic…”
Guerini‐Rocco, E., Hodi, Z., Piscuoglio, S., Ng, C. K. Y., Rakha, E. A., Schultheis, A. M., Marchiò, C., Paula, A. D. C., Filippo, M. R. D., Martelotto, L. G., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4566 · Cited by 75
Synnott, N. C., Bauer, M. R., Madden, S. F., Murray, A. M., Klinger, R. W., O’Donovan, N., O’Connor, D. P., Gallagher, W. M., Crown, J. P., Fersht, A. R., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.053 · Cited by 72
LaRochelle, J. R., Fodor, M., Xu, X., Durzynska, I., Fan, L., Stams, T., Chan, H. M., LaMarche, M. J., Chopra, R., Wang, P., et al. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01287 · Cited by 70
“associated SHP2 (1-525) mutants were generated using site directed mutagenesis (QuikChange”
MethodTRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer
Witwicki, R. M., Ekram, M. B., Qiu, X., Janiszewska, M., Shu, S., Kwon, M., Trinh, A., Frias, E., Ramadan, N., Hoffman, G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.023 · Cited by 77
Cornelia de Lange syndrome: from molecular diagnosis to therapeutic approach
Sarogni, P., Pallotta, M. M., & Musio, A. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106277 · Cited by 81
Mathematical model of colorectal cancer initiation
Paterson, C., Clevers, H. C., & Božić, I. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003771117 · Cited by 81
Reversal of nucleobase methylation by dioxygenases
Xu, G., & Bochtler, M. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-00675-5 · Cited by 71
Genomic landscape of TCRαβ and TCRγδ T-large granular lymphocyte leukemia
Cheon, H., Xing, J. C., Moosic, K. B., Ung, J., Chan, V., Chung, D., Toro, M. F., Elghawy, O., Wang, J. S., Hamele, C. E., et al. (2022) · Blood · doi:10.1182/blood.2021013164 · Cited by 77
Ginghină, O., Hudiță, A., Zamfir, M., Spânu, A., Mardare, M., Bondoc, I., Buburuzan, L., Georgescu, S. E., Costache, M., Negrei, C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.856575 · Cited by 80
“To ease the interpretation of the genomic alterations detected in patient tumors, several support tools such as My Cancer Genome (23), CIViC (24, 25), the Precision Medicine Knowledge Base (26, 27), The Jackson Laboratory Clinical Knowledgebase (28, 29), Cancer Genome Interpreter (30), Cancer Driver Log (31, 32), Tumo…”
MethodImmune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
Sklavenitis-Pistofidis, R., Aranha, M. P., Redd, R. A., Baginska, J., Haradhvala, N. J., Hallisey, M., Dutta, A. K., Savell, A., Varmeh, S., Heilpern-Mallory, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.017 · Cited by 70
Self-citationThe nature of self for T cells — a systems-level perspective
Granados, D. P., Laumont, C. M., Thibault, P., & Perreault, C. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.10.012 · Cited by 75
Myant, K., Cammareri, P., Hodder, M. C., Wills, J. C., von Kriegsheim, A., Győrffy, B., Rashid, M., Polo, S., Maspero, E., Vaughan, L. S., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606684 · Cited by 80
Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development
Sarogni, P., Palumbo, O., Servadio, A., Astigiano, S., D’Alessio, B., Gatti, V., Cukrov, D., Baldari, S., Pallotta, M. M., Aretini, P., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1116-0 · Cited by 73
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma
Maitituoheti, M., Keung, E. Z.-Y., Tang, M., Liang, Y., Alam, H., Han, G., Singh, A. K., Raman, A. T., Terranova, C. J., Sarkar, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108293 · Cited by 90
“…Network, 2015a; da Silva Almeida et al., 2015; Gao et al., 2014; Grasso et al., 2012; Jones et al., 2012; Juhlin et al., 2015; Kandoth et al., 2013; Lawrence et al., 2014; Lin et al., 2014; Lohr et al., 2012; Morin et al., 2011; Parsons et al., 2011; Pasqualucci et al., 2011; Pugh et al., 2012;…”
Wang, X., Liu, C., Chen, J., Chen, L., Ren, X., Hou, M., Cui, X., Jiang, Y., Liu, E., Zong, Y., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00445-8 · Cited by 79
Li, Y., Liu, Y., Yu, X., Xu, Y., Pan, X., Sun, Y. E., Wang, Y., Song, Y.-H., & Shen, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02013-w · Cited by 96
Fuchs, C. S., Tabernero, J. M., Tomášek, J., Chau, I., Melichar, B., Safran, H. P., Tehfe, M. A., Dumitru, F., Топузов, Э. Э., Schlittler, L. A., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.293 · Cited by 75
“These studies highlighted the molecular complexity of gastric cancer cells, but still leave many unanswered questions regarding the roles of the microenvironment and tumour vasculature (Lawrence et al, 2014; Lee et al, 2014; Wang et al, 2014).”
BackgroundInfluentialA Transcription Factor Addiction in Leukemia Imposed by the MLL Promoter Sequence
Lu, B., Klingbeil, O., Tarumoto, Y., Somerville, T. D. D., Huang, Y.-H., Wei, Y., Wai, D. C., Low, J. K. K., Milazzo, J. P., Wu, X. S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.015 · Cited by 69
“Cancer genes identified by (Lawrence et al., 2014) (n=260) were then investigated for exceptional motif count enrichment using a ranked promoter motif count list for each motif in the JASPAR database.”
MethodThe genomic evolution of human prostate cancer
Mitchell, T., & Neal, D. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.234 · Cited by 63
“%) and MED12 (3.6%; Lawrence et al, 2014).”
InfluentialCSN1 Somatic Mutations in Penile Squamous Cell Carcinoma
Feber, A., Worth, D. C., Chakravarthy, A., de Winter, P., Shah, K., Arya, M., Saqib, M., Nigam, R., Malone, P. R., Tan, W. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3134 · Cited by 72
“Of the private alterations (637/810) several have been identified as putative drivers in the pan-cancer analysis of 4742 cancers (8), and include tumor suppressors CDKN2A and NF1,”
InfluentialClonal Hematopoiesis and Blood-Cancer Risk
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1500684 · Cited by 68
The structural basis for Ras activation of PI3Kα lipid kinase
Zhang, M., Jang, H., & Nussinov, R. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp00101h · Cited by 74
Runx3 at the interface of immunity, inflammation and cancer
Lotem, J., Levanon, D., Negreanu, V., Bauer, O., Hantisteanu, S., Dicken, J., & Groner, Y. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.004 · Cited by 79
Nichol, J. N., Dupéré-Richer, D., Ezponda, T., Licht, J. D., & Miller, W. H. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.001 · Cited by 83
“ARID1A encodes a component of the SWI/SNF chromatin-remodeling complex that is also frequently mutated in many tumors (Lawrence et al., 2014), including ovarian clear cell carcinoma (OCCC).”
BackgroundGlobal impact of somatic structural variation on the DNA methylome of human cancers
Zhang, Y., Yang, L., Kucherlapati, M. H., Hadjipanayis, A. G., Pantazi, A., Bristow, C. A., Lee, E. A., Mahadeshwar, H. S., Tang, J., Zhang, J., et al. (2019) · Genome biology · doi:10.1186/s13059-019-1818-9 · Cited by 74
Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate
Pandey, A., Stawiski, E. W., Durinck, S., Gowda, H., Goldstein, L. D., Barbhuiya, M. A., Schröder, M., Sreenivasamurthy, S. K., Kim, S., Phalke, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17880-4 · Cited by 75
Genome Sequencing during a Patient’s Journey through Cancer
Nangalia, J., & Campbell, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1910138 · Cited by 66
Intra-tumor genetic heterogeneity in rectal cancer
Hardiman, K. M., Ulintz, P., Kuick, R. D., Hovelson, D. H., Gates, C., Bhasi, A., Grant, A. R., Liu, J., Cani, A. K., Greenson, J. K., et al. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.131 · Cited by 74
Abraham, C. G., Ludwig, M. P., Andrysík, Z., Pandey, A., Joshi, M., Galbraith, M. D., Sullivan, K. D., & Espinosa, J. M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.058 · Cited by 69
“Inactivating mutations in the effector binding domain have been identified in several cancer types, including HNSCC (Kakiuchi et al., 2014; Lawrence et al., 2014).”
BackgroundResultInfluentialPredictive biomarkers for drug response in bladder cancer
Yoshida, T., Kates, M. R., Fujita, K., Bivalacqua, T. J., & McConkey, D. J. (2019) · International Journal of Urology · doi:10.1111/iju.14082 · Cited by 65
Kovar, H. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.947963 · Cited by 72
The Hippo pathway in disease and therapy: cancer and beyond
Gómez-Ferrer, M., Gómez, V., & Hergovich, A. (2014) · Clinical and Translational Medicine · doi:10.1186/2001-1326-3-22 · Cited by 69
Substrate specificity of TOR complex 2 is determined by a ubiquitin-fold domain of the Sin1 subunit
Tatebe, H., Murayama, S., Yonekura, T., Hatano, T., Richter, D., Furuya, T., Kataoka, S., Furuita, K., Kojima, C., & Shiozaki, K. (2017) · eLife · doi:10.7554/elife.19594 · Cited by 69
Genetic landscape and deregulated pathways in B‐cell lymphoid malignancies
Rosenquist, R., Beà, S., Du, M., Nadel, B., & Pan‐Hammarström, Q. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12633 · Cited by 72
Synonymous mutations reveal genome-wide levels of positive selection in healthy tissues
Poon, G. Y. P., Watson, C. J., Fisher, D. S., & Blundell, J. R. (2021) · Nature Genetics · doi:10.1038/s41588-021-00957-1 · Cited by 65
Vaske, O. M., Bjork, I., Salama, S. R., Beale, H. C., Shah, A. T., Sanders, L., Pfeil, J., Lam, D. L., Learned, K., Durbin, A., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.13968 · Cited by 69
Targeting Phosphatases and Kinases: How to Checkmate Cancer
Turdo, A., D’Accardo, C., Glaviano, A., Porcelli, G., Colarossi, C., Colarossi, L., Mare, M., Faldetta, N., Modica, C., Pistone, G., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.690306 · Cited by 74
Metadata
- Authors
- Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Lander, Eric S.
- Getz, Gad
- ORCID
- Venue
- Nature
- Published
- 2014-01
- Volume
- 505
- Issue
- 7484
- Pages
- 495-501
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4048962
- OpenAlex
- W2114031931
- Cited by
- 3,096
- References
- 13
- Citations by year
- 2026: 103 · 2025: 188 · 2024: 202 · 2023: 223 · 2022: 235 · 2021: 241 · 2020: 277 · 2019: 268 · 2018: 264 · 2017: 312 · 2016: 305 · 2015: 291 · 2014: 177
- FWCI
- 116.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (R01CA157304)
- National Institute of General Medical Sciences (T32GM007753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- cancer genes, somatic point mutations, cancer types, saturation analysis, mutation frequency, exome sequencing, sample size determination, mutation rate heterogeneity, cancer genomics
- MeSH terms
- Chromatin, DNA Mutational Analysis, Humans, Neoplasms, RNA Processing, Post-Transcriptional, Genome, Human, Case-Control Studies, Apoptosis, Point Mutation, Sample Size, Genomics, Genomic Instability, Cell Proliferation, Genes, Neoplasm, Immune Evasion, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.